HC Wainwright & Co. Initiates Coverage On EFFECTOR Therapeutics With Buy Rating, Announces Price Target of $5
HC Wainwright & Co. Initiates Coverage On EFFECTOR Therapeutics With Buy Rating, Announces Price Target of $5
HC Wainwright & Co.以买入评级开始对EFFECTOR Therapeutics进行保险,宣布目标股价为5美元
HC Wainwright & Co. analyst Robert Burns initiates coverage on eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy rating and announces Price Target of $5.
HC Wainwright & Co. 分析师罗伯特·伯恩斯以买入评级开始对Effector Therapeutics(纳斯达克股票代码:EFTR)进行报道,并宣布目标股价为5美元。